GERD, Erosive Esophagitis, and Peptic Ulcer Disease

The alarm-feature fork

The key decision is whether empiric management is safe or structural disease needs direct inspection.

Dysphagia, odynophagia, gastrointestinal bleeding, unexplained iron deficiency anemia, weight loss, and persistent vomiting are alarm features that favor upper endoscopy.

Typical heartburn and regurgitation without alarm features can begin with lifestyle measures and an empiric PPI trial; failure of an optimized trial or diagnostic uncertainty changes the pathway.

A younger patient with uncomplicated dyspepsia can enter a noninvasive H pylori test-and-treat pathway, while age, cancer risk, alarm features, bleeding, or suspected obstruction lower the threshold for endoscopy.

A negative endoscopy does not automatically exclude reflux; ambulatory reflux monitoring is used when objective confirmation is needed and the diagnosis remains uncertain.

Alarm features do not diagnose cancer; they remove permission to guess.

Four labels that are not synonyms

The symptoms overlap, but the injured compartment and the proof required are different.

GERD is reflux of gastric contents that causes troublesome symptoms or complications; typical symptoms are heartburn and regurgitation.

Erosive esophagitis is visible esophageal mucosal injury from reflux and is one objective GERD phenotype, not a diagnosis made from symptom intensity.

Peptic ulcer disease is a mucosal defect in the stomach or duodenum, most often driven by H pylori or NSAID injury; meal timing alone is an unreliable separator.

H pylori is an infection that can cause chronic gastritis and gastric or duodenal ulcers, but infection can exist without an ulcer and an NSAID ulcer can occur without infection.

Name the compartment before naming the treatment.

Numbers that change the next action

A few intervals and thresholds prevent the most common management errors.

An empiric PPI course for classic uncomplicated GERD is commonly assessed over 8 weeks, with dosing before a meal and optimization before declaring failure.

Optimized bismuth quadruple therapy for H pylori is given for 14 days when susceptibility is unknown and that regimen is appropriate.

Test of cure should occur at least 4 weeks after antibiotics are completed, with PPIs held for 2 weeks when clinically safe to reduce false-negative testing.

A Glasgow-Blatchford score of 0 or 1 identifies a very-low-risk upper gastrointestinal bleeding group that may be managed without hospital admission when the full clinical context agrees.

Four weeks after antibiotics and two weeks off PPI: do not test cure too early.

Localize the clue before interpreting the pain

The anatomic target is often more useful than the patient's adjective for discomfort.

Retrosternal burning and regurgitation point toward the esophagus; epigastric pain can arise from stomach or duodenum but does not reliably identify ulcer location.

Hematemesis, coffee-ground emesis, or melena indicates upper gastrointestinal bleeding until proven otherwise; tachycardia, orthostasis, syncope, or shock signals important blood loss.

Sudden severe epigastric pain with guarding, rigidity, and free intraperitoneal air suggests perforation and demands resuscitation plus urgent surgical evaluation.

Gastric ulcers are generally biopsied or followed to exclude malignancy when appropriate; uncomplicated duodenal ulcers are far less likely to be malignant.

Burning localizes poorly; bleeding and peritoneal signs do not.

Acid is the final common pathway, not the only cause

Ulceration reflects aggressive acid-peptic forces overcoming mucosal defense.

Histamine at H2 receptors raises cAMP, while acetylcholine at M3 receptors and gastrin at CCK-B receptors raise intracellular calcium; all converge on the parietal-cell H+/K+ ATPase.

A PPI covalently inhibits active proton pumps, so dosing before a meal improves pump activation and drug effect.

Gastric prostaglandins support mucus, bicarbonate, epithelial restitution, and mucosal blood flow; NSAID cyclooxygenase inhibition weakens this defense even when acid output is not increased.

H pylori urease permits survival in acid. Antral-predominant inflammation can reduce somatostatin and increase gastrin and acid delivery to the duodenum, while corpus-predominant atrophic disease may reduce acid yet increase gastric ulcer and cancer risk.

Acid makes the injury possible; the cause tells you why it happened.

Treatment changes when the driver changes

Use the minimum effective acid strategy, but never leave H pylori, NSAID exposure, bleeding, or perforation unaddressed.

For typical uncomplicated GERD, optimize lifestyle measures and PPI timing, then use the lowest effective maintenance strategy once symptoms are controlled; severe erosive disease may require long-term maintenance.

When antibiotic susceptibility is unknown, the 2024 ACG H pylori guideline prefers optimized 14-day bismuth quadruple therapy and advises against empiric clarithromycin- or levofloxacin-containing salvage regimens without demonstrated susceptibility.

Treat every confirmed H pylori infection and document eradication with a urea breath test, fecal antigen test, or appropriate biopsy-based test after therapy.

For NSAID-associated ulcer disease, stop the NSAID when possible and give PPI therapy; if anti-inflammatory treatment must continue, minimize NSAID exposure and add gastroprotection according to gastrointestinal and cardiovascular risk.

Overt bleeding requires resuscitation and risk assessment followed by timely endoscopy; perforation or uncontrolled bleeding moves beyond routine outpatient acid suppression.

Treat the lesion, remove the driver, and prove the infection is gone.